121 related articles for article (PubMed ID: 20163369)
1. Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans.
Meyer CH; Krohne TU; Holz FG
Acta Ophthalmol; 2012 Feb; 90(1):68-70. PubMed ID: 20163369
[TBL] [Abstract][Full Text] [Related]
2. Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans.
Meyer CH; Krohne TU; Holz FG
Retina; 2011 Oct; 31(9):1877-84. PubMed ID: 21738089
[TBL] [Abstract][Full Text] [Related]
3. Effects of intravitreally injected bevacizumab on vascular endothelial growth factor in fellow eyes.
Matsuyama K; Ogata N; Matsuoka M; Wada M; Nishimura T; Takahashi K
J Ocul Pharmacol Ther; 2011 Aug; 27(4):379-83. PubMed ID: 21810018
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes.
Miyake T; Sawada O; Kakinoki M; Sawada T; Kawamura H; Ogasawara K; Ohji M
Invest Ophthalmol Vis Sci; 2010 Mar; 51(3):1606-8. PubMed ID: 19875666
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of intravitreal bevacizumab (Avastin).
Bakri SJ; Snyder MR; Reid JM; Pulido JS; Singh RJ
Ophthalmology; 2007 May; 114(5):855-9. PubMed ID: 17467524
[TBL] [Abstract][Full Text] [Related]
6. Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys.
Kakinoki M; Sawada O; Sawada T; Saishin Y; Kawamura H; Ohji M
Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5877-80. PubMed ID: 22836776
[TBL] [Abstract][Full Text] [Related]
7. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab.
Nonobe NI; Kachi S; Kondo M; Takai Y; Takemoto K; Nakayama A; Hayakawa M; Terasaki H
Retina; 2009 May; 29(5):579-85. PubMed ID: 19430279
[TBL] [Abstract][Full Text] [Related]
8. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans.
Krohne TU; Eter N; Holz FG; Meyer CH
Am J Ophthalmol; 2008 Oct; 146(4):508-12. PubMed ID: 18635152
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits.
Nomoto H; Shiraga F; Kuno N; Kimura E; Fujii S; Shinomiya K; Nugent AK; Hirooka K; Baba T
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4807-13. PubMed ID: 19324856
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of intravitreal ranibizumab (Lucentis).
Bakri SJ; Snyder MR; Reid JM; Pulido JS; Ezzat MK; Singh RJ
Ophthalmology; 2007 Dec; 114(12):2179-82. PubMed ID: 18054637
[TBL] [Abstract][Full Text] [Related]
11. Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration.
Abrishami M; Zarei-Ghanavati S; Soroush D; Rouhbakhsh M; Jaafari MR; Malaekeh-Nikouei B
Retina; 2009 May; 29(5):699-703. PubMed ID: 19430280
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes.
Moisseiev E; Waisbourd M; Ben-Artsi E; Levinger E; Barak A; Daniels T; Csaky K; Loewenstein A; Barequet IS
Graefes Arch Clin Exp Ophthalmol; 2014 Feb; 252(2):331-7. PubMed ID: 24170282
[TBL] [Abstract][Full Text] [Related]
13. Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema.
Roh MI; Kim HS; Song JH; Lim JB; Kwon OW
Ophthalmology; 2009 Jan; 116(1):80-6. PubMed ID: 19118699
[TBL] [Abstract][Full Text] [Related]
14. Aqueous humor concentration of bevacizumab after subconjunctival injection in rabbit.
Kim MJ; Han ES; Kim J; Kim TW
J Ocul Pharmacol Ther; 2010 Feb; 26(1):49-53. PubMed ID: 20148650
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab.
Sawada O; Kawamura H; Kakinoki M; Ohji M
Graefes Arch Clin Exp Ophthalmol; 2008 Oct; 246(10):1379-81. PubMed ID: 18581130
[TBL] [Abstract][Full Text] [Related]
16. Aqueous vascular endothelial growth factor and ranibizumab concentrations after monthly and bimonthly intravitreal injections of ranibizumab for age-related macular degeneration.
Wang X; Sawada T; Kakinoki M; Miyake T; Kawamura H; Saishin Y; Liu P; Ohji M
Graefes Arch Clin Exp Ophthalmol; 2014 Jul; 252(7):1033-9. PubMed ID: 24196779
[TBL] [Abstract][Full Text] [Related]
17. Influence of ocular volume and lens status on pharmacokinetics and duration of action of intravitreal vascular endothelial growth factor inhibitors.
Krohne TU; Muether PS; Stratmann NK; Holz FG; Kirchhof B; Meyer CH; Fauser S
Retina; 2015 Jan; 35(1):69-74. PubMed ID: 25077535
[TBL] [Abstract][Full Text] [Related]
18. Long-term tolerability and serum concentration of bevacizumab (avastin) when injected in newborn rabbit eyes.
Wu WC; Lai CC; Chen KJ; Chen TL; Wang NK; Hwang YS; Yeung L; Li LM
Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3701-8. PubMed ID: 20181842
[TBL] [Abstract][Full Text] [Related]
19. Levels of erythropoietin and vascular endothelial growth factor in surgery-required advanced neovascular glaucoma eyes before and after intravitreal injection of bevacizumab.
Zhou M; Chen S; Wang W; Huang W; Cheng B; Ding X; Zhang X
Invest Ophthalmol Vis Sci; 2013 Jun; 54(6):3874-9. PubMed ID: 23674760
[TBL] [Abstract][Full Text] [Related]
20. Aqueous humor levels of vascular endothelial growth factor before and after intravitreal bevacizumab in type 3 versus type 1 and 2 neovascularization. A prospective, case-control study.
dell'Omo R; Cassetta M; dell'Omo E; di Salvatore A; Hughes JM; Aceto F; Porcellini A; Costagliola C
Am J Ophthalmol; 2012 Jan; 153(1):155-61.e2. PubMed ID: 21861975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
